Table 1

Functional outcome measures over 112 weeks of the LIBERTY study (open-label analysis set)

Outcomes	Time point (weeks)	Participants continuing on erenumab 140 mg, N=118	Participants switching from placebo to erenumab 140 mg, N=122	Overall population entering OLEP, N=240
Change from baseline in HIT-6*	12	−5.2 (6.6), n=116	−2.3 (5.9), n=122	−3.7 (6.4), n=238
	16	−5.9 (6.6), n=114	−6.9 (7.6), n=120	−6.4 (7.2), n=234
	36	−7.9 (8.2), n=103	−8.6 (9.0), n=105	−8.3 (8.6), n=208
	48	−7.9 (7.6), n=97	−10.6 (9.2), n=99	−9.2 (8.6), n=196
	60	−8.5 (7.4), n=88	−9.7 (10.0), n=82	−9.0 (8.7), n=170
	72	−8.2 (7.7), n=94	−9.3 (9.3), n=97	−8.7 (8.5), n=191
	84	−8.8 (8.0), n=91	−8.9 (8.5), n=97	−8.8 (8.2), n=188
	96	−9.2 (8.0), n=88	−10.4 (9.6), n=89	−9.8 (8.8), n=177
	108	−8.5 (8.0), n=91	−10.4 (9.3), n=90	−9.5 (8.7), n=181
Change from baseline in MPFID-PI†	9–12	−2.0 (8.8), n=117	1.3 (8.9), n=120	−0.3 (9.0), n=237
	13–16	−1.3 (8.5), n=116	−2.4 (8.7), n=121	−1.9 (8.6), n=237
	37–40	−3.2 (8.7), n=102	−4.7 (8.6), n=103	−3.9 (8.7), n=205
	49–52	−4.6 (7.8), n=93	−5.5 (8.7), n=94	−5.1 (8.2), n=187
	61–64	−5.2 (6.9), n=70	−4.5 (8.4), n=67	−4.9 (7.6), n=137
	73–76	−3.2 (8.3), n=95	−4.8 (9.7), n=92	−4.0 (9.0), n=187
	85–88	−3.8 (8.1), n=89	−4.5 (9.4), n=93	−4.1 (8.8), n=182
	97–100	−2.2 (10.5), n=90	−4.3 (10.3), n=89	−3.2 (10.4), n=179
	109–112	−4.1 (9.1), n=88	−5.0 (11.4), n=86	−4.5 (10.3), n=174
Change from baseline in MPFID-EA†	9–12	−3.3 (8.8), n=117	0.4 (8.9), n=120	−1.4 (9.0), n=237
	13–16	−2.6 (9.1), n=116	−3.7 (8.5), n=121	−3.2 (8.8), n=237
	37–40	−4.6 (8.8), n=102	−5.5 (8.8), n=103	−5.0 (8.8), n=205
	49–52	−5.7 (7.6), n=93	−6.7 (8.5), n=94	−6.2 (8.1), n=187
	61–64	−6.6 (7.7), n=70	−5.1 (9.3), n=67	−5.9 (8.5), n=137
	73–76	−4.4 (9.1), n=95	−5.6 (9.8), n=92	−5.0 (9.5), n=187
	85–88	−4.9 (8.2), n=89	−5.4 (9.4), n=93	−5.2 (8.8), n=182
	97–100	−3.4 (11.1), n=90	−5.4 (10.5), n=89	−4.4 (10.8), n=179
	109–112	−4.9 (9.7), n=88	−6.0 (10.9), n=86	−5.4 (10.3), n=174

Data are presented as mean (SD). Change from baseline=postbaseline−baseline. The baseline period is defined as the period between week −4 visit and the day prior to first dose. The baseline value is the prorated number to 28-day equivalents during baseline period.
*HIT-6 total score was assessed by visit.
†At each time point, mean (SD) values for week are determined for a daily collection during the respective 4-week periods.
EA, everyday activities; HIT-6, Headache Impact Test; MPFID, Migraine Physical Function Impact Diary; N, number of participants included in the analysis set; n, number of participants who responded; OLEP, open-label extension phase; ; PI, physical impairment.